Prediction of synergistic antitumour effect of gefitinib and radiation in vitro

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2883-2888

  Lin, Hui Qiang ^a   Haider, Meriaty ^a   Andrew, Katsifis ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Combination therapy; EGFR; Gefitinib; Melanoma; Predictor; Radiation

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; SKIN CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MELANOMA; PHOSPHORYLATION; QUINAZOLINES; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 80051651483     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA and Cullinane C: EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 55: 713-723, 2003. (Pubitemid 36172491)
2. Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J and Ongkeko WM: Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 118: 1372-1376, 2008.
3. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR and Ciardiello F: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3250-3258, 2002. (Pubitemid 35155038)
4. Williams KJ, Telfer BA, Stratford IJ and Wedge SR: ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157-1161, 2002. (Pubitemid 34438090)
5. Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J and Vassal G: EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 123: 209-216, 2008. (Pubitemid 351705211)
6. Joensuu G, Joensuu T, Nokisalmi P, Reddy C, Isola J, Ruutu M, Kouri M, Kupelian PA, Collan J, Pesonen S and Hemminki A: A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 78: 42-49, 2010.
7. Ma S, Xu Y, Deng Q and Yu X: Treatment of brain metastasis from non-small cell lung cancer with whole-brain radiotherapy and gefitinib in a Chinese population. Lung Cancer 65: 198-203, 2009.
8. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E and Johnston P: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11: 7480-7489, 2005. (Pubitemid 41507709)
9. Zampino MG, Magni E, Santoro L, Zorzino L, Dell'Orto P, Sonzogni A, Fazio N, Monfardini L, Chiappa A, Biffi R and de Braud F: Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib? Cancer Chemother Pharmacol 63: 139-148, 2008.
10. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M and Fuchs CS: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11: 6650-6656, 2005. (Pubitemid 41339006)
11. Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E and Ardizzoni A: A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-κB activation. Br J Cancer 98: 71-76, 2008.
12. Lin HQ, Katsifis A and Meriaty H: Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression. Anticancer Res 30: 4899-4905, 2010.
13. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
14. Fukutome M, Maebayashi K, Nasu S, Seki K and Mitsuhashi N: Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ('Iressa') and trastuzumab ('Herceptin'). Int J Radiat Oncol Biol Phys 66: 528-536, 2006. (Pubitemid 44332749)
15. Ochs JS: Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 58: 941-949, 2004.
16. Swetter SM: Malignant melanoma. eMedicine website. http://emedicine. medscape.com/article/1100753-overview 2010.
17. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M and Scherubl H: Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41: 1008-1016, 2004. (Pubitemid 39575669)